
May 15 (Reuters) - vTv Therapeutics Inc VTVT.O:
VTV THERAPEUTICS ANNOUNCES REINITIATION OF SCREENING IN CATT1 PHASE 3 TRIAL EVALUATING POTENTIAL FIRST-IN-CLASS LIVER-SELECTIVE GLUCOKINASE ACTIVATOR CADISEGLIATIN FOR TYPE 1 DIABETES
VTV THERAPEUTICS INC - TOPLINE CATT1 PHASE 3 DATA EXPECTED IN 2H 2026
VTV THERAPEUTICS INC - PROTOCOL AMENDMENT SHORTENS TRIAL DURATION TO 6 MONTHS